Durect 2025 Q2 Earnings Net Loss Narrows by 38.8%

Durect (DRRX) reported its fiscal 2025 Q2 earnings on August 13, 2025. The company saw a 30.8% year-over-year decline in revenue and narrowed its net loss by 38.8%, while the CEO highlighted a pending acquisition by Bausch Health as a transformative milestone.

Revenue for the second quarter of 2025 fell to $447,000, a 30.8% decline from $646,000 in the same period in 2024. Collaborative research and development and other revenue accounted for the bulk of income at $428,000, with product revenue contributing $19,000. The sharp decline underscores challenges in the company’s core operations.

On the earnings front, Durect reduced its per-share loss to $0.07 in Q2 2025, compared to $0.12 in Q2 2024—a 41.7% improvement. The company also narrowed its net loss to $2.27 million, down from $3.70 million a year earlier. Despite ongoing financial pressures, the reduction in losses reflects better cost management and strategic adjustments.

Durect’s shares have gained traction in recent trading sessions, with the stock rising 1.06% on the latest day and 2.15% in the past week, while delivering a staggering 239.23% gain for the month. Historically, the buy-on-earnings strategy has proven effective, with an average gain of 12.5% per quarter, outperforming the SPY ETF’s 4.5%. The strategy captured a maximum quarterly gain of 22.5% in Q1 2023 and a minimum of 2.5% in Q2 2024.

The CEO emphasized the transformative potential of the pending acquisition by Bausch Health, which includes an upfront payment of $63 million and up to $350 million in sales milestones. This deal is expected to close in Q3 2025 and allow Durect’s therapies to scale commercially. While the company’s cash position remains a concern, the CEO expressed confidence in larsucosterol, which has Fast Track and Breakthrough Therapy designations.

Additional News
Within the three-week window following Durect’s Q2 earnings report, the most notable non-earnings-related news included:
1. Acquisition Activity: Durect's pending acquisition by Bausch Health for $63 million upfront plus up to $350 million in milestones became the most-discussed development.
2. Strategic Alignment: The CEO highlighted the strategic and commercial benefits of the acquisition, emphasizing the potential to commercialize Durect’s therapies at scale.
3. Clinical Designations: The continued recognition of larsucosterol with Fast Track and Breakthrough Therapy designations bolstered investor confidence in the company’s pipeline despite ongoing financial challenges.